Xenon Pharmaceuticals (XENE) Q3 2026 earnings summary

Executive summary

• Azetukalner (AZK) focal-seizure NDA submitted to FDA in September 2026; launch preparation and commercial infrastructure build-out underway.

• X-NOVA2 enrollment completed at ~360 patients; MDD topline results expected in December 2026, moved forward from Q1 2027.

• Priorities include expanding AZK across epilepsy and neuropsychiatry and advancing NaV1.7 and Kv7 pain candidates into phase II studies.

Financial highlights

• Q3 net loss widened to $110.4M from $90.9M YoY; 9M net loss was $323.5M versus $240.6M, driven by higher R&D and G&A spending.

• Q3 R&D was $95.6M versus $77.1M and G&A was $24.4M versus $19.3M; 9M R&D was $283.4M versus $213.2M and G&A was $72.2M versus $57.6M.

• Q3 collaboration revenue was $0; 9M 2026 revenue was nil versus $7.5M in 9M 2025, when a Neurocrine milestone was recognized.

• Q3 operating loss was $120.1M versus $96.3M; 9M operating loss was $355.6M versus $263.3M.

• Interest income rose to $11.6M in Q3 from $6.2M and to $30.7M in 9M from $21.5M, reflecting higher average investment balances, partly offset by lower yields.

Outlook and guidance

• X-NOVA2 MDD topline results expected in December 2026; study was 90% powered to detect a ~2.5-point placebo-corrected HAM-D17 difference at week six.

• X-FIRST phase III-B/IV is planned to start in Q1 2027; phase II acute-pain studies for XEN1701 and XEN1120 are expected to begin in H1 2027.

• X-TOLE3 enrollment outside Japan expected to complete in 2026; X-ACKT continues enrolling, and NBI-921355 phase 1b data are expected in 2027.

• Cash runway expected into 2029 under current operating plans; operating expenses are expected to rise as AZK advances, launch preparation progresses and development and commercial capabilities expand.